EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-Throughput Empirical and Virtual Screening To Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer

Yushu Ma, Chien-Hung Shih, Jinxiong Cheng, Hsiao-Chun Chen, Li-Ju Wang, Yanhao Tan, Yuan Zhang, Daniel D Brown iD, Steffi Oesterreich, Adrian V Lee, Yu-Chiao Chiu iD, Yu-Chih Chen iD

Analytical Chemistry · 2025

DOI: 10.1021/acs.analchem.4c05138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Yushu Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, University of Pittsburgh, 5115 Centre Ave, Pittsburgh, Pennsylvania 15232, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, High-Throughput Screening Assays, Antineoplastic Agents, Polyploidy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy resistance in breast cancer is increasingly attributed to polyploid giant cancer cells (PGCCs), which arise through whole-genome doubling and exhibit heightened resilience to standard treatments. Characterized by enlarged nuclei and increased DNA content, these cells tend to be dormant under therapeutic stress, driving disease relapse. Despite their critical role in resistance, strategies to effectively target PGCCs are limited, largely due to the lack of high-throughput methods for assessing their viability. Traditional assays lack the sensitivity needed to detect PGCC-specific elimination, prompting the development of novel approaches. To address this challenge, we developed a high-throughput single-cell morphological analysis workflow designed to differentiate compounds that selectively inhibit non-PGCCs, PGCCs, or both. Using this method, we screened a library of 2,726 FDA Phase 1-approved drugs, identifying promising anti-PGCC candidates, including proteasome inhibitors, FOXM1, CHK, and macrocyclic lactones. Notably, RNA-Seq analysis of cells treated with the macrocyclic lactone Pyronaridine revealed AXL inhibition as a potential strategy for targeting PGCCs. Although our single-cell morphological analysis pipeline is powerful, empirically testing all existing compounds is impractical and inefficient. To overcome this limitation, we trained a machine learning model to predict anti-PGCC efficacy in silico , integrating chemical fingerprints and compound descriptions from prior publications and databases. The model demonstrated a high correlation with experimental outcomes and predicted efficacious compounds in an expanded library of over 6,000 drugs. Among the top-ranked predictions, we experimentally validated two compounds as potent PGCC inhibitors. These findings underscore the synergistic potential of integrating high-throughput empirical screening with machine learning-based virtual screening to accelerate the discovery of novel therapies, particularly for targeting therapy-resistant PGCCs in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHigh-Throughput Screening AssaysAntineoplastic AgentsPolyploidyHumansFemaleDrug Screening Assays, AntitumorCell Line, TumorDrug DiscoverySingle-Cell Analysis

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, University of Pittsburgh, 5115 Centre Ave, Pittsburgh, Pennsylvania 15232, United States.
  • Department of Computational and Systems Biology, University of Pittsburgh, 3420 Forbes Avenue, Pittsburgh, Pennsylvania 15260, United States.
  • Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, 3700 O'Hara Street, Pittsburgh, Pennsylvania 15260, United States.
  • Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh, 5150 Centre Avenue, Pittsburgh, Pennsylvania 15232, United States.
  • Department of Immunology, University of Pittsburgh, 5051 Centre Ave, Pittsburgh, Pennsylvania 15213, United States.
  • Institute for Precision Medicine, University of Pittsburgh, 5051 Centre Ave, Pittsburgh, Pennsylvania 15213, United States.

ORCID-Profile: Daniel D Brown, Yu-Chiao Chiu, Yu-Chih Chen

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • National Center for Advancing Translational Sciences
  • Pittsburgh Liver Research Center, University of Pittsburgh
  • National Cancer Institute

Zitieren

APA

Ma, Y., Shih, C. H., Cheng, J., Chen, H. C., Wang, L. J., Tan, Y., Zhang, Y., Brown, D. D., Oesterreich, S., Lee, A. V., Chiu, Y. C., & Chen, Y. C. (2025). High-Throughput Empirical and Virtual Screening To Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c05138

Vancouver

Ma Y, Shih CH, Cheng J, Chen HC, Wang LJ, Tan Y, et al. High-Throughput Empirical and Virtual Screening To Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.4c05138

BibTeX
@article{Ma2025,
  author = {Ma, Yushu and Shih, Chien-Hung and Cheng, Jinxiong and Chen, Hsiao-Chun and Wang, Li-Ju and Tan, Yanhao and Zhang, Yuan and Brown, Daniel D and Oesterreich, Steffi and Lee, Adrian V and Chiu, Yu-Chiao and Chen, Yu-Chih},
  title = {High-Throughput Empirical and Virtual Screening To Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer},
  journal = {Analytical Chemistry},
  year = {2025},
  doi = {10.1021/acs.analchem.4c05138}
}
Kostenlos starten →